Skip to content
The Nexus
DossierENTITY

Myricx Bio

Coverage of Myricx Bio in the Nexus archive.

Earliest in view: Jul 6 · 12:56 UTCMost recent: Jul 6 · 13:37 UTC
Co-mentioned in this coverage
Republicansorganization2Novartisorganization2Medicareorganization1Jerome Adamsperson1peptides regulationtopic1Dario Amodeiperson1Anthropicorganization1FDAorganization1antibody-drug conjugatetopic1clinical trial diversitytopic1
Recent coverage
  • HEALTHJul 6 · 13:37 UTCSTAT NEWS
    STAT+: Four major biotech updates to catch up on

    The article highlights four biotech updates: Medicare proposing cuts to 340B payments, Republicans advocating for diversity in clinical trials, former surgeon general Jerome Adams advising on peptides regulation, and Novartis acquiring Myricx Bio for $1.1 billion to expand its cancer drug development. Anthropic CEO Dario Amodei expresses cautious optimism about AI's role in biotechnology.

  • BUSINESSJul 6 · 12:56 UTCSTAT NEWS
    STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more

    Novartis acquired Myricx Bio for $1.1 billion to advance its antibody-drug conjugate (ADC) pipeline with a novel NMTi payload. Congressional Republicans passed a bill funding the FDA, including a report urging the agency to implement requirements for diversifying clinical trials.